

Dirk De Ruyscher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2045302/publications.pdf>

Version: 2024-02-01

140
papers

6,087
citations

81900

39
h-index

82547

72
g-index

143
all docs

143
docs citations

143
times ranked

8494
citing authors

#	ARTICLE	IF	CITATIONS
1	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. <i>Cancer Treatment Reviews</i> , 2015, 41, 503-510.	7.7	482
2	Radiotherapy toxicity. <i>Nature Reviews Disease Primers</i> , 2019, 5, 13.	30.5	434
3	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
4	European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5301-5310.	1.6	276
5	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. <i>British Journal of Radiology</i> , 2017, 90, 20160665.	2.2	270
6	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 1-10.	0.6	177
7	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolmmunology</i> , 2020, 9, 1703449.	4.6	156
8	Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. <i>Oncolmmunology</i> , 2016, 5, e1069938.	4.6	148
9	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 1-5.	0.6	141
10	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
11	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. <i>Radiotherapy and Oncology</i> , 2018, 128, 26-36.	0.6	112
12	Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review. <i>Radiation Oncology</i> , 2020, 15, 214.	2.7	103
13	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 344-352.	0.8	102
14	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 709-713.	0.8	99
15	Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2366-2377.	1.6	99
16	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 431-439.	0.6	98
17	Charged particles in radiotherapy: A 5-year update of a systematic review. <i>Radiotherapy and Oncology</i> , 2012, 103, 5-7.	0.6	97
18	Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 267-278.	0.8	93

#	ARTICLE	IF	CITATIONS
19	Prophylactic cranial irradiation for patients with lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, e277-e293.	10.7	91
20	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 62-69.	1.7	86
21	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 935-944.	0.8	83
22	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
23	PET scans in radiotherapy planning of lung cancer. <i>Lung Cancer</i> , 2012, 75, 141-145.	2.0	81
24	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. <i>Clinical Cancer Research</i> , 2014, 20, 6389-6397.	7.0	81
25	The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology. <i>Radiotherapy and Oncology</i> , 2018, 128, 37-43.	0.6	80
26	A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making. <i>Radiotherapy and Oncology</i> , 2014, 112, 37-43.	0.6	77
27	Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1958-1961.	1.1	72
28	PET scans in radiotherapy planning of lung cancer. <i>Radiotherapy and Oncology</i> , 2010, 96, 335-338.	0.6	64
29	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). <i>Radiotherapy and Oncology</i> , 2019, 131, 166-173.	0.6	59
30	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.6	53
31	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. <i>Acta Oncologica</i> , 2019, 58, 1275-1282.	1.8	50
32	Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. <i>Cells</i> , 2021, 10, 930.	4.1	50
33	Tumour Movement in Proton Therapy: Solutions and Remaining Questions: A Review. <i>Cancers</i> , 2015, 7, 1143-1153.	3.7	49
34	CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage. <i>Radiotherapy and Oncology</i> , 2015, 117, 29-35.	0.6	48
35	PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 267-273.	0.6	48
36	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	7.1	47

#	ARTICLE	IF	CITATIONS
37	A Longitudinal Evaluation of Partial Lung Irradiation in Mice by Using a Dedicated Image-Guided Small Animal Irradiator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 696-704.	0.8	44
38	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2696-2715.	2.8	43
39	Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?. <i>British Journal of Radiology</i> , 2017, 90, 20160441.	2.2	41
40	Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. <i>Radiotherapy and Oncology</i> , 2012, 102, 228-233.	0.6	40
41	Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 154.	2.8	40
42	State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future. <i>Clinical Lung Cancer</i> , 2013, 14, 89-95.	2.6	38
43	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. <i>Frontiers in Oncology</i> , 2017, 7, 83.	2.8	36
44	Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2009, 91, 353-359.	0.6	35
45	Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator. <i>Radiotherapy and Oncology</i> , 2017, 124, 482-487.	0.6	35
46	A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. <i>Acta Oncologica</i> , 2018, 57, 226-230.	1.8	35
47	Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?. <i>Radiotherapy and Oncology</i> , 2016, 120, 273-278.	0.6	34
48	Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors. <i>Cancer Treatment Reviews</i> , 2017, 56, 8-15.	7.7	33
49	Photons, protons or carbon ions for stage I non-small cell lung cancer – Results of the multicentric ROCOCO in silico study. <i>Radiotherapy and Oncology</i> , 2018, 128, 139-146.	0.6	32
50	Residual Glandular Breast Tissue After Mastectomy: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 2288-2296.	1.5	32
51	Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). <i>Radiotherapy and Oncology</i> , 2014, 110, 482-487.	0.6	30
52	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	2.6	29
53	Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. <i>Journal of Thoracic Disease</i> , 2016, 8, E833-E835.	1.4	26
54	Spatial location of local recurrences after mastectomy: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 263-273.	2.5	26

#	ARTICLE	IF	CITATIONS
55	Immunotherapy as sensitizer for local radiotherapy. <i>Oncolimmunology</i> , 2020, 9, 1832760.	4.6	25
56	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	1.8	24
57	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.6	24
58	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. <i>Radiation Oncology</i> , 2019, 14, 33.	2.7	24
59	A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges. <i>Breast</i> , 2021, 56, 42-52.	2.2	24
60	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII. <i>Radiotherapy and Oncology</i> , 2010, 97, 36-39.	0.6	23
61	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1940-1953.	1.1	23
62	Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 379-384.	0.6	23
63	The posterior cerebellum, a new organ at risk?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 22-26.	1.7	23
64	Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1538-1549.	1.1	22
65	Regional variability in radiation-induced lung damage can be predicted by baseline CT numbers. <i>Radiotherapy and Oncology</i> , 2017, 122, 300-306.	0.6	21
66	Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. <i>Radiotherapy and Oncology</i> , 2019, 135, 141-146.	0.6	21
67	Postoperative radiotherapy for lung cancer: Is it worth the controversy?. <i>Cancer Treatment Reviews</i> , 2016, 51, 10-18.	7.7	20
68	Imaging of regional ventilation: Is CT ventilation imaging the answer? A systematic review of the validation data. <i>Radiotherapy and Oncology</i> , 2019, 137, 175-185.	0.6	20
69	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8510-8510.	1.6	20
70	Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 117-125.	0.6	19
71	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> . 2022, 23, e264-e268.	2.6	17
72	Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities. <i>Journal of Thoracic Disease</i> , 2014, 6, 319-27.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. <i>Cancers</i> , 2021, 13, 6259.	3.7	17
74	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. <i>Radiotherapy and Oncology</i> , 2016, 121, 440-446.	0.6	15
75	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. <i>Acta Oncologica</i> , 2017, 56, 1591-1596.	1.8	15
76	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
77	Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. <i>Radiotherapy and Oncology</i> , 2009, 93, 389-395.	0.6	14
78	Radiotherapy dose and fractionation for stage III NSCLC. <i>Lancet Oncology</i> , The, 2015, 16, e156-e157.	10.7	14
79	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.6	14
80	Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older. <i>Journal of Geriatric Oncology</i> , 2019, 10, 547-554.	1.0	14
81	Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. <i>Lung Cancer</i> , 2021, 155, 103-113.	2.0	14
82	Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO <i>in silico</i> study. <i>British Journal of Radiology</i> , 2020, 93, 20190879.	2.2	13
83	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise. <i>Radiotherapy and Oncology</i> , 2020, 150, 26-29.	0.6	13
84	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	5.4	13
85	Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. <i>Radiotherapy and Oncology</i> , 2016, 121, 322-327.	0.6	12
86	Comparing the Outcomes of Stereotactic Ablative Radiotherapy and Non-Stereotactic Ablative Radiotherapy Definitive Radiotherapy Approaches to Thoracic Malignancy: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, 199-212.	2.6	12
87	Radiation-Induced Lung Density Changes on CT Scan for NSCLC: No Impact of Dose-Escalation Level or Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 642-650.	0.8	12
88	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	2.8	12
89	Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 55-67.	7.3	12
90	Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab. <i>Acta Oncologica</i> , 2016, 55, 156-162.	1.8	11

#	ARTICLE	IF	CITATIONS
91	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 49-55.	1.7	11
92	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.6	11
93	An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100653.	1.2	11
94	An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 2048-2058.	2.8	11
95	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
96	A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 112-119.	1.7	11
97	Radiotherapy and PD-L1 inhibition in metastatic NSCLC. <i>Lancet Oncology</i> , The, 2017, 18, 840-842.	10.7	10
98	Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. <i>Translational Lung Cancer Research</i> , 2017, 6, 661-669.	2.8	10
99	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.6	10
100	The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 284-286.	1.1	9
101	Development and internal validation of a multinomial NTCP model for the severity of acute dyspnea after radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 176-184.	0.6	9
102	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. <i>Radiotherapy and Oncology</i> , 2020, 145, 45-48.	0.6	9
103	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	2.6	9
104	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.6	8
105	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue. <i>Radiation Oncology</i> , 2018, 13, 131.	2.7	8
106	Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 134-144.	1.7	8
107	The promise of multiparametric imaging in oncology: how do we move forward?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1195-1198.	6.4	7
108	A multidisciplinary approach for autologous breast reconstruction: A narrative (re)view for better management. <i>Radiotherapy and Oncology</i> , 2021, 157, 263-271.	0.6	7

#	ARTICLE	IF	CITATIONS
109	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	0.6	7
110	Individualized Positron Emission Tomography-Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy: A Model-Based Evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 857-865.	0.8	6
111	Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study. <i>Acta Oncologica</i> , 2016, 55, 1450-1455.	1.8	6
112	Clinician perspectives on clinical decision support systems in lung cancer: Implications for shared decision-making. <i>Health Expectations</i> , 2022, 25, 1342-1351.	2.6	6
113	In Regard to Koshy et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 945-946.	0.8	5
114	Location of the Tumor is a Central Predictor of Nodal (N1) Upstaging. <i>Journal of Thoracic Oncology</i> , 2016, 11, e89-e90.	1.1	5
115	Regional lung avoidance by CT numbers to reduce radiation-induced lung damage risk in non-small cell lung cancer: a simulation study. <i>Acta Oncologica</i> , 2020, 59, 201-207.	1.8	5
116	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. <i>Cancers</i> , 2021, 13, 2132.	3.7	5
117	PET-CT in Radiotherapy for Lung Cancer. <i>Methods in Molecular Biology</i> , 2011, 727, 53-58.	0.9	5
118	Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands. <i>Lung Cancer</i> , 2021, 162, 61-70.	2.0	5
119	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	2.0	5
120	A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC. <i>Radiotherapy and Oncology</i> , 2018, 127, 259-266.	0.6	4
121	PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 478-479.	1.1	4
122	Predicting Lung Cancer Survival Using Probabilistic Reclassification of TNM Editions With a Bayesian Network. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 436-443.	2.1	4
123	Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI. <i>Neuro-Oncology</i> , 0, , .	1.2	4
124	Radical treatment of synchronous oligometastases from NSCLC. <i>Lancet Oncology</i> , The, 2016, 17, 1625-1626.	10.7	3
125	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 18-22.	1.7	3
126	Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 131, 120-126.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 590-590.	1.7	3
128	Treatment of limited disease small cell lung cancer. <i>European Journal of Cancer</i> , 2009, 45, 425-426.	2.8	2
129	Proposals for the M-descriptors of the Eight TNM Classification for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e42-e43.	1.1	2
130	Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. <i>Acta Oncologica</i> , 2017, 56, 1610-1613.	1.8	2
131	In Regard to Redmond et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 238-239.	0.8	2
132	Prognostic Models for Patient Selection in Postoperative Radiotherapy: Ready for Use?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1809-1811.	1.1	2
133	Changing equipoise in the landscape of radiation for oligometastatic lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S184-S191.	2.8	2
134	The ROCOCO performance scoring system translates dosimetric differences into clinically relevant endpoints: Comparing IMPT to VMAT in an example pilocytic astrocytoma dataset. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 32-38.	1.7	2
135	Longitudinal multi-parametric imaging in radiation oncology: boon or bane?. <i>Acta Oncologica</i> , 2017, 56, 501-502.	1.8	1
136	Lung-sparing intensity-modulated radiotherapy in malignant pleural mesothelioma: palliative or potentially radical?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4038-S4039.	1.4	1
137	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	2.8	1
138	A closer look at the safety and effectiveness of modern PORT in stage III-N2 non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E585-E586.	1.4	0
139	Optimized local therapy for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1783-1785.	1.4	0
140	Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 326-327.	1.1	0